https://www.yiliao.com/index.php?action=history&feed=atom&title=VEGF%2FVEGFR%E4%BF%A1%E5%8F%B7%E8%BD%B4
VEGF/VEGFR信号轴 - 版本历史
2026-04-18T05:11:27Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=VEGF/VEGFR%E4%BF%A1%E5%8F%B7%E8%BD%B4&diff=315677&oldid=prev
2026年1月25日 (日) 15:51 185.180.13.100
2026-01-25T15:51:57Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月25日 (日) 15:51的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l123" >第123行：</td>
<td colspan="2" class="diff-lineno">第123行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">上游机制</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">上游机制</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;"><strong>[[缺氧]]</strong> (Hypoxia) <del class="diffchange diffchange-inline">$\to$ </del>HIF-1α <del class="diffchange diffchange-inline">$\to$ </del>VEGF 转录</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;"><strong>[[缺氧]]</strong> (Hypoxia) <ins class="diffchange diffchange-inline">→ </ins>HIF-1α <ins class="diffchange diffchange-inline">→ </ins>VEGF 转录</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td></tr>
</table>
185.180.13.100
https://www.yiliao.com/index.php?title=VEGF/VEGFR%E4%BF%A1%E5%8F%B7%E8%BD%B4&diff=315676&oldid=prev
185.180.13.100：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T15:49:51Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>VEGF/VEGFR 信号轴</strong>，即<strong>血管内皮生长因子</strong>（VEGF）及其受体（VEGFR）通路，是调控人体<strong>[[血管生成]]</strong>（Angiogenesis）的最核心机制，也是肿瘤获得氧气和营养供应的“生命线”。在缺氧环境下，肿瘤细胞通过分泌 VEGF 诱导周围血管向其生长。除了“喂养”肿瘤，VEGF 还是一个强效的<strong>免疫抑制因子</strong>，它能抑制树突状细胞成熟并阻止 T 细胞穿透血管壁进入肿瘤。因此，抗血管生成药物（如<strong>[[贝伐珠单抗]]</strong>、<strong>[[仑伐替尼]]</strong>）不仅旨在“饿死”肿瘤，更重要的作用是实现<strong>“血管正常化”</strong>，修缮畸形、渗漏的肿瘤血管，从而改善药物递送并协同 <strong>[[免疫治疗]]</strong>。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">VEGF / VEGFR Axis</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Angiogenesis Master Switch (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:VEGF_VEGFR_Signaling_Diagram.png|100px|配体受体结合示意图]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">血管生成开关</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心配体</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>VEGF-A</strong> (最关键)<br>VEGF-C/D (淋巴管)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心受体</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>VEGFR-2</strong> (主导信号)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">上游驱动</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">缺氧 / <strong>[[HIF-1α]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">单抗 (mAb)<br>小分子 TKI</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">特征副作用</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[高血压]]</strong>, 蛋白尿<br>出血/血栓, 伤口不愈</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">当前地位</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;">免疫治疗的最佳搭档</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">生理与病理：从救命到夺命</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
VEGF 是人体内最强的血管通透性因子，其效力是组胺的 5 万倍。在肿瘤中，它引发了灾难性的后果。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>血管生成开关 (Angiogenic Switch)：</strong><br />
<br>当肿瘤生长超过 1-2mm³ 时，内部缺氧诱导 HIF-1α 上调 VEGF。VEGF 结合内皮细胞上的 VEGFR-2，启动下游 RAS/RAF/MEK 和 PI3K/AKT 通路，促使内皮细胞增殖、迁移，形成新血管。</li><br />
<li style="margin-bottom: 12px;"><strong>畸形的血管网：</strong><br />
<br>肿瘤催生的血管是混乱、扭曲且高度渗漏的。这导致肿瘤内部<strong>间质液压升高</strong>（High IFP），药物难以渗透进去。同时，渗漏的血管壁使得 T 细胞难以附着和穿透，形成了<strong>免疫屏障</strong>。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">治疗全景：大分子 vs 小分子</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">血管正常化理论 (Vessel Normalization)</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
Rakesh Jain 教授提出的理论革新了该领域：适度的抗血管治疗能“修剪”过度增生的异常血管，使其恢复正常结构。这不仅改善了供氧（提高放疗敏感性），更重要的是<strong>打开了 T 细胞进入肿瘤的大门</strong>。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物类别</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 25%;">代表药物</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 50%;">机制与特点</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">单克隆抗体<br>(大分子, IV)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[贝伐珠单抗]]</strong><br>(Avastin)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>中和配体 (VEGF-A)</strong>。特异性高，脱靶毒性小。是“免疫+抗血管”联合方案（如肝癌 T+A）的首选搭档。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">多靶点 TKI<br>(小分子, 口服)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[仑伐替尼]]</strong><br>索拉非尼</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>阻断受体 (VEGFR)</strong>。同时抑制 FGFR/PDGFR 等旁路，抗瘤活性更强，但副作用（手足综合征、腹泻）更大。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">融合蛋白<br>(Trap)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">阿柏西普</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">像“陷阱”一样捕获 VEGF-A, B 和 PlGF，阻断范围更广。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Ferrara N, Henzel WJ. (1989).</strong> <em>Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.</em> <strong>[[Biochemical and Biophysical Research Communications]]</strong>. 1989.<br><br />
<span style="color: #475569;">[发现之源]：Napoleone Ferrara 发现了 VEGF，并随后在基因泰克开发了贝伐珠单抗，开启了抗血管生成治疗的时代。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Jain RK. (2005).</strong> <em>Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.</em> <strong>[[Science]]</strong>. 2005;307(5706):58-62.<br><br />
<span style="color: #475569;">[理论革新]：Rakesh Jain 提出了著名的“血管正常化”假说，完美解释了为何抗血管药物能增效化疗和免疫治疗，而非仅仅是“饿死”肿瘤。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Finn RS, Qin S, Ikeda M, et al. (2020).</strong> <em>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.</em> <strong>[[New England Journal of Medicine]]</strong>. 2020;382:1894-1905.<br><br />
<span style="color: #475569;">[IMbrave150 研究]：具有里程碑意义的 III 期临床。证实了“免疫+抗血管”组合（T+A）在晚期肝癌中优于索拉非尼，确立了该组合在实体瘤中的统治地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
VEGF/VEGFR · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">上游机制</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[缺氧]]</strong> (Hypoxia) $\to$ HIF-1α $\to$ VEGF 转录</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">经典组合</td><br />
<td style="padding: 10px 15px; color: #334155;">"可乐必妥"组合 (仑伐+K药) • T+A 组合 (阿郑+贝伐)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">旁路靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR]] • [[PDGFR]] • [[EGFR]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">副作用管理</td><br />
<td style="padding: 10px 15px; color: #334155;">监测血压 (ACEI/ARB 治疗) • 监测尿蛋白 • 手术前后需停药 (防出血/不愈合)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
185.180.13.100